1-10 of 10
Steven R. Alberts
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis

Free
Harry H. Yoon, Qian Shi, Erica N. Heying, Andrea Muranyi, Joerg Bredno, Faith Ough, Azita Djalilvand, June Clements, Rebecca Bowermaster, Wen-Wei Liu, Michael Barnes, Steven R. Alberts, Kandavel Shanmugam, Frank A. Sinicrope
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 125–133.
https://doi.org/10.1158/1078-0432.CCR-18-1984
Published: 03 January 2019
View article titled, Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
Open the PDF for Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis in another window
Includes: Supplementary data
Journal Articles

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

Free
Frank A. Sinicrope, Michelle R. Mahoney, Harry H. Yoon, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, Garth D. Nelson, Daniel J. Sargent, Steven R. Alberts
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5294–5304.
https://doi.org/10.1158/1078-0432.CCR-15-0527
Published: 30 November 2015
View article titled, Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
Open the PDF for Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance) in another window
Includes: Supplementary data
Journal Articles

Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials

Free
Philip A. Philip, Kari Chansky, Michael LeBlanc, Lawrence Rubinstein, Lesley Seymour, S. Percy Ivy, Steven R. Alberts, Paul J. Catalano, John Crowley
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (16): 4176–4185.
https://doi.org/10.1158/1078-0432.CCR-13-2024
Published: 13 August 2014
View article titled, Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials
Open the PDF for Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials in another window
Journal Articles

Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial)

Free
Dan Sha, Adam M. Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Robert B. Diasio
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3319–3327.
https://doi.org/10.1158/1078-0432.CCR-14-0069
Published: 12 June 2014
View article titled, Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial)
Open the PDF for Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial) in another window
Journal Articles

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

Free
Harry H. Yoon, David Tougeron, Qian Shi, Steven R. Alberts, Michelle R. Mahoney, Garth D. Nelson, Suresh G. Nair, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Frank A. Sinicrope, for the Alliance for Clinical Trials in Oncology
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 3033–3043.
https://doi.org/10.1158/1078-0432.CCR-13-3140
Published: 29 May 2014
View article titled, KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Open the PDF for KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance) in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

Free
Prema P. Peethambaram, Michelle E. Melisko, Kristine J. Rinn, Steven R. Alberts, Nicole M. Provost, Lori A. Jones, Robert B. Sims, Lisa R. C. Lin, Mark W. Frohlich, John W. Park
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5937–5944.
https://doi.org/10.1158/1078-0432.CCR-08-3282
Published: 14 September 2009
View article titled, A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu
Open the PDF for A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu in another window
Journal Articles

Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers

Free
Frank A. Sinicrope, Rafaela L. Rego, Nathan R. Foster, Stephen N. Thibodeau, Steven R. Alberts, Harold E. Windschitl, Daniel J. Sargent
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (13): 4128–4133.
https://doi.org/10.1158/1078-0432.CCR-07-5160
Published: 01 July 2008
View article titled, Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers
Open the PDF for Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers in another window
Journal Articles

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

Free
Grace K. Dy, James P. Thomas, George Wilding, Laura Bruzek, Sumithra Mandrekar, Charles Erlichman, Dona Alberti, Kim Binger, Henry C. Pitot, Steven R. Alberts, Lorelei J. Hanson, Rebecca Marnocha, Kendra Tutsch, Scott H. Kaufmann, Alex A. Adjei
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3410–3416.
https://doi.org/10.1158/1078-0432.CCR-04-2068
Published: 02 May 2005
View article titled, A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Open the PDF for A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer in another window
Journal Articles

A Phase I Trial of the Farnesyl Protein Transferase Inhibitor R115777 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

Free
Alex A. Adjei, Gary A. Croghan, Charles Erlichman, Randolph S. Marks, Joel M. Reid, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, Laura M. Bruzek, Pamela Atherton, Alain Thibault, Peter A. Palmer, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2520–2526.
Published: 01 July 2003
View article titled, A Phase I Trial of the Farnesyl Protein Transferase Inhibitor R115777 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of the Farnesyl Protein Transferase Inhibitor R115777 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer in another window
Journal Articles

A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer

Free
Alex A. Adjei, Grace K. Dy, Charles Erlichman, Joel M. Reid, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, Pamela J. Atherton, Tanya Watanabe, Richard S. Geary, Jon Holmlund, F. Andrew Dorr
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 115–123.
Published: 01 January 2003
View article titled, A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer in another window